{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,2]],"date-time":"2026-11-02T23:21:05Z","timestamp":1793661665890,"version":"4.5.1"},"reference-count":60,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2023,4,17]],"date-time":"2023-04-17T00:00:00Z","timestamp":1681689600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100004731","name":"Natural Science Foundation of Zhejiang Province","doi-asserted-by":"publisher","award":["LQ19H290001"],"award-info":[{"award-number":["LQ19H290001"]}],"id":[{"id":"10.13039\/501100004731","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100017594","name":"Medical Science and Technology Project of Zhejiang Province","doi-asserted-by":"publisher","award":["2022KY921"],"award-info":[{"award-number":["2022KY921"]}],"id":[{"id":"10.13039\/501100017594","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Endocrinol."],"abstract":"<jats:sec><jats:title>Background<\/jats:title><jats:p>Metabolic-associated fatty liver disease (MAFLD) is closely associated with omentin, a novel adipokine that plays a vital role in metabolic balance. The literature about the relationship between circulating omentin and MAFLD is conflicting. Therefore, this meta-analysis evaluated circulating omentin levels in patients with MAFLD compared with healthy controls to explore the role of omentin in MAFLD.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>The literature search was performed up to April 8, 2022, using PubMed, Cochrane Library, EMBASE, CNKI, Wanfang, CBM, Clinical Trials Database and Grey Literature Database. This meta-analysis pooled the statistics in Stata and presented the overall results using the standardized mean difference (<jats:italic>SMD<\/jats:italic>) and 95% confidence interval (<jats:italic>CI<\/jats:italic>).<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Twelve studies with 1624 individuals (927 cases and 697 controls) were included, and all of them were case-control studies. In addition, ten of twelve included studies were conducted on Asian participants. Patients with MAFLD had significantly lower circulating omentin levels than healthy controls (<jats:italic>SMD<\/jats:italic>=-0.950 [-1.724, -0.177], <jats:italic>P<\/jats:italic>=0.016). Subgroup analysis and meta-regression demonstrated that fasting blood glucose (FBG) might be the source of heterogeneity and was inversely associated with omentin levels (coefficient=-0.538, <jats:italic>P<\/jats:italic>=0.009). No significant publication bias existed (<jats:italic>P<\/jats:italic>&amp;gt;0.05), and outcomes were robust in the sensitivity analysis.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>Lower circulating omentin levels were associated with MAFLD, and FBG might be the source of heterogeneity. Since Asian studies accounted for a significant portion of the meta-analysis, the conclusion might be more applicable to the Asian population. By investigating the relationship between omentin and MAFLD, this meta-analysis laid the foundation for the development of diagnostic biomarkers and treatment targets.<\/jats:p><\/jats:sec><jats:sec><jats:title>Systematic review registration<\/jats:title><jats:p><jats:uri>https:\/\/www.crd.york.ac.uk\/prospero\/<\/jats:uri>, identifier CRD42022316369.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fendo.2023.1073498","type":"journal-article","created":{"date-parts":[[2023,4,17]],"date-time":"2023-04-17T06:01:03Z","timestamp":1681711263000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":10,"title":["Association of circulating omentin level and metabolic-associated fatty liver disease: a systematic review and meta-analysis"],"prefix":"10.3389","volume":"14","author":[{"given":"Qin","family":"Zhang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuaihang","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yani","family":"Ke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qicong","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chenglu","family":"Shen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuting","family":"Ruan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kaihan","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jie","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shan","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2023,4,17]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cgh.2021.12.002","article-title":"2019 global NAFLD prevalence: A systematic review and meta-analysis","volume":"20","author":"Le","year":"2021","journal-title":"Clin Gastroenterol Hepatol"},{"key":"B2","doi-asserted-by":"publisher","first-page":"1999","DOI":"10.1053\/j.gastro.2019.11.312","article-title":"MAFLD: A consensus-driven proposed nomenclature for metabolic associated fatty liver disease","volume":"158","author":"Eslam","year":"2020","journal-title":"Gastroenterology"},{"key":"B3","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1016\/j.cgh.2015.07.019","article-title":"Hepatocellular carcinoma in the absence of cirrhosis in united states veterans is associated with nonalcoholic fatty liver disease","volume":"14","author":"Mittal","year":"2016","journal-title":"Clin Gastroenterol Hepatol"},{"key":"B4","doi-asserted-by":"publisher","first-page":"1090","DOI":"10.1053\/j.gastro.2017.01.003","article-title":"Changes in the prevalence of hepatitis c virus infection, nonalcoholic steatohepatitis, and alcoholic liver disease among patients with cirrhosis or liver failure on the waitlist for liver transplantation","volume":"152","author":"Goldberg","year":"2017","journal-title":"Gastroenterology"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2020.01.052","article-title":"Nonalcoholic fatty liver disease 2020: The state of the disease","volume":"158","author":"Cotter","year":"2020","journal-title":"Gastroenterology"},{"key":"B6","doi-asserted-by":"publisher","first-page":"101143","DOI":"10.1016\/j.molmet.2020.101143","article-title":"Metabolic drivers of non-alcoholic fatty liver disease","volume":"50","author":"Bence","year":"2021","journal-title":"Mol Metab"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1038\/s41575-020-00406-0","article-title":"Nonalcoholic fatty liver disease: another leap forward","volume":"18","author":"Abdelmalek","year":"2021","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0907929","article-title":"Pioglitazone, vitamin e, or placebo for nonalcoholic steatohepatitis","volume":"362","author":"Sanyal","year":"2010","journal-title":"N Engl J Med"},{"key":"B9","doi-asserted-by":"publisher","first-page":"101122","DOI":"10.1016\/j.molmet.2020.101122","article-title":"Nonalcoholic fatty liver disease (NAFLD) from pathogenesis to treatment concepts in humans","volume":"50","author":"Pafili","year":"2021","journal-title":"Mol Metab"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1152\/ajpendo.00572.2004","article-title":"Identification of omentin as a novel depot-specific adipokine in human adipose tissue: possible role in modulating insulin action","volume":"290","author":"Yang","year":"2006","journal-title":"Am J Physiol Endocrinol Metab"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1002\/cphy.c160043","article-title":"Adipose tissue-derived omentin-1 function and regulation","volume":"7","author":"Watanabe","year":"2017","journal-title":"Compr Physiol"},{"key":"B12","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1038\/s41413-018-0012-0","article-title":"Omentin-1 prevents inflammation-induced osteoporosis by downregulating the pro-inflammatory cytokines","volume":"6","author":"Rao","year":"2018","journal-title":"Bone Res"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2019.00383","article-title":"The effects of intelectin-1 on antioxidant and angiogenesis in HUVECs exposed to oxygen glucose deprivation","volume":"10","author":"Gu","year":"2019","journal-title":"Front Neurol"},{"key":"B14","doi-asserted-by":"publisher","first-page":"108187","DOI":"10.1016\/j.abb.2019.108187","article-title":"Omentin-1 attenuates lipopolysaccharide (LPS)-induced U937 macrophages activation by inhibiting the TLR4\/MyD88\/NF-\u03baB signaling","volume":"679","author":"Wang","year":"2020","journal-title":"Arch Biochem Biophys"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1016\/j.diabres.2011.03.001","article-title":"Omentin-1 is associated with carotid atherosclerosis in patients with metabolic syndrome","volume":"93","author":"Liu","year":"2011","journal-title":"Diabetes Res Clin Pract"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2012-3673","article-title":"Increased chemerin and decreased omentin-1 in both adipose tissue and plasma in nascent metabolic syndrome","volume":"98","author":"Jialal","year":"2013","journal-title":"J Clin Endocrinol Metab"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1111\/apa.14026","article-title":"Serum levels of omentin-1 are increased after weight loss and are particularly associated with increases in obese children with metabolic syndrome","volume":"106","author":"Zhang","year":"2017","journal-title":"Acta Paediatr"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1136\/jim-2021-002071","article-title":"Relationship between circulating serum omentin-1 levels and nascent metabolic syndrome in patients with hypertension","volume":"70","author":"Cetin Sanlialp","year":"2022","journal-title":"J Investig Med"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0226292","article-title":"Omentin-1 in diabetes mellitus: A systematic review and meta-analysis","volume":"14","author":"Pan","year":"2019","journal-title":"PloS One"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.18203","article-title":"Association of plasma omentin-1 levels with diabetes and its complications","volume":"13","author":"Eimal Latif","year":"2021","journal-title":"Cureus"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1080\/14728222.2022.2037556","article-title":"Omentin-1: a newly discovered warrior against metabolic related diseases","volume":"26","author":"Zhao","year":"2022","journal-title":"Expert Opin Ther Targets"},{"key":"B22","doi-asserted-by":"publisher","first-page":"n160","DOI":"10.1136\/bmj.n160","article-title":"PRISMA 2020 explanation and elaboration: updated guidance and exemplars for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"Bmj"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1007\/s10654-010-9491-z","article-title":"Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses","volume":"25","author":"Stang","year":"2010","journal-title":"Eur J Epidemiol"},{"key":"B24","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1186\/1471-2288-14-135","article-title":"Estimating the sample mean and standard deviation from the sample size, median, range and\/or interquartile range","volume":"14","author":"Wan","year":"2014","journal-title":"BMC Med Res Methodol"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1177\/0962280216669183","article-title":"Optimally estimating the sample mean from the sample size, median, mid-range, and\/or mid-quartile range","volume":"27","author":"Luo","year":"2018","journal-title":"Stat Methods Med Res"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1016\/0197-2456(86)90046-2","article-title":"Meta-analysis in clinical trials","volume":"7","author":"DerSimonian","year":"1986","journal-title":"Control Clin Trials"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.315.7109.629","article-title":"Bias in meta-analysis detected by a simple, graphical test","volume":"315","author":"Egger","year":"1997","journal-title":"Bmj"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1002\/oby.21674","article-title":"Reduced expression of chemerin in visceral adipose tissue associates with hepatic steatosis in patients with obesity","volume":"24","author":"Bekaert","year":"2016","journal-title":"Obesity"},{"key":"B29","article-title":"Correlation of serum SHGB levels with insulin sensitivity, lipid metabolism, oxidative stress in patients with nonalcoholic fatty liver disease","volume":"18","author":"Hang","year":"2019","journal-title":"J Clin Exp Med"},{"key":"B30","first-page":"1","article-title":"Plasma omentin leveland related factorsin type 2 diabetes mellitus com bined with fatty hver diseas","volume":"35","author":"Li","year":"2012","journal-title":"Chin J Postgraduates Med"},{"key":"B31","article-title":"Relationship between RBP-4 and omentin in patients with NAFLD and insulin resistance","volume":"16","author":"Liu","year":"2015","journal-title":"Guide China Med"},{"key":"B32","doi-asserted-by":"publisher","first-page":"70","DOI":"10.4103\/jrms.JRMS_788_16","article-title":"Serum omentin-1, vaspin, and apelin levels and central obesity in patients with nonalcoholic fatty liver disease","volume":"22","author":"Montazerifar","year":"2017","journal-title":"J Res Med Sci"},{"key":"B33","article-title":"Association of plasma omentin-1 levels with adiponectin and inflammatory cytokines in diabetic patients with fatty liver","author":"Shao","year":"2013","journal-title":"Tianjin Med J"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.26402\/jpp.2019.2.11","article-title":"Omentin, vaspin and irisin in chronic liver diseases","volume":"70","author":"Waluga","year":"2019","journal-title":"J Physiol Pharmacol"},{"key":"B35","article-title":"Study on the expression and significance of serum Omentin-1 and Apelin in nonalcoholic fatty liver disease","volume":"37","author":"Wang","year":"2021","journal-title":"J Modern Med Health"},{"key":"B36","volume-title":"Study of the relationship between omentin, visfatin, and nonalcoholic fatty liver disease in patients with type 2 diabetes mellitus [D]","author":"Wang","year":"2013"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1016\/S0168-8278(11)60879-9","article-title":"Serum levels of omentin, chemerin and adipsin in patients with biopsy-proven nonalcoholic fatty liver disease","volume":"54","author":"Yilmaz","year":"2011","journal-title":"J Hepatol"},{"key":"B38","article-title":"Relation between adpose cell factor and insulin resistance in patients with non-alcoholic fatty liver disease","volume":"15","author":"Yu","year":"2013","journal-title":"Chin J Geriatric Heart Brain Vessel Dis"},{"key":"B39","article-title":"Related factors for heart rate recovery after treadmill exercise testing in patients with nonalcoholic fatty liver disease","volume":"24","author":"Zhang","year":"2016","journal-title":"Chin J Hepatol"},{"key":"B40","doi-asserted-by":"publisher","first-page":"S17","DOI":"10.2337\/dc22-S002","article-title":"2. Classification and diagnosis of diabetes: Standards of medical care in diabetes-2022","volume":"45","year":"2022","journal-title":"Diabetes Care"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1002\/hep.23567","article-title":"Nonobese population in a developing country has a high prevalence of nonalcoholic fatty liver and significant liver disease","volume":"51","author":"Das","year":"2010","journal-title":"Hepatology"},{"key":"B42","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1038\/s41575-021-00523-4","article-title":"Advancing the global public health agenda for NAFLD: a consensus statement","volume":"19","author":"Lazarus","year":"2022","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1111\/liv.14548","article-title":"Comparison of MAFLD and NAFLD diagnostic criteria in real world","volume":"40","author":"Lin","year":"2020","journal-title":"Liver Int"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2017.09.021","article-title":"Hypertension, diabetes, atherosclerosis and NASH: Cause or consequence","volume":"68","author":"Lonardo","year":"2018","journal-title":"J Hepatol"},{"key":"B45","doi-asserted-by":"publisher","first-page":"154770","DOI":"10.1016\/j.metabol.2021.154770","article-title":"Non-alcoholic fatty liver disease, insulin resistance, metabolic syndrome and their association with vascular risk","volume":"119","author":"Muzurovi\u0107","year":"2021","journal-title":"Metabolism"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-018-0104-9","article-title":"Mechanisms of NAFLD development and therapeutic strategies","volume":"24","author":"Friedman","year":"2018","journal-title":"Nat Med"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1038\/s41574-021-00507-z","article-title":"Emerging therapeutic approaches for the treatment of NAFLD and type 2 diabetes mellitus","volume":"17","author":"Ferguson","year":"2021","journal-title":"Nat Rev Endocrinol"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1038\/s41575-021-00502-9","article-title":"Metabolomics and lipidomics in NAFLD: biomarkers and non-invasive diagnostic tests","volume":"18","author":"Masoodi","year":"2021","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.1016\/j.metabol.2015.11.006","article-title":"Adipokines in nonalcoholic fatty liver disease","volume":"65","author":"Polyzos","year":"2016","journal-title":"Metabolism"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.1016\/j.freeradbiomed.2020.10.021","article-title":"Omentin: A novel therapeutic approach for the treatment of endothelial dysfunction in type 2 diabetes","volume":"162","author":"Leandro","year":"2021","journal-title":"Free Radic Biol Med"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2013.04.013","article-title":"Community-based lifestyle modification programme for non-alcoholic fatty liver disease: a randomized controlled trial","volume":"59","author":"Wong","year":"2013","journal-title":"J Hepatol"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2017.05.016","article-title":"Treatment of NAFLD with diet, physical activity and exercise","volume":"67","author":"Romero-G\u00f3mez","year":"2017","journal-title":"J Hepatol"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.2337\/dc05-2179","article-title":"Contributions of beta-cell dysfunction and insulin resistance to the pathogenesis of impaired glucose tolerance and impaired fasting glucose","volume":"29","author":"Abdul-Ghani","year":"2006","journal-title":"Diabetes Care"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.1016\/j.metabol.2015.12.012","article-title":"The multiple-hit pathogenesis of non-alcoholic fatty liver disease (NAFLD)","volume":"65","author":"Buzzetti","year":"2016","journal-title":"Metabolism"},{"key":"B55","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1186\/s12944-020-01326-3","article-title":"Association between fasting plasma glucose and nonalcoholic fatty liver disease in a nonobese Chinese population with normal blood lipid levels: a prospective cohort study","volume":"19","author":"Zou","year":"2020","journal-title":"Lipids Health Dis"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.1210\/clinem\/dgac122","article-title":"Visit-to-Visit fasting glucose variability in young adulthood and nonalcoholic fatty liver disease in middle age","volume":"107","author":"Zhou","year":"2022","journal-title":"J Clin Endocrinol Metab"},{"key":"B57","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/j.diabres.2010.01.013","article-title":"Changes of serum omentin-1 levels in normal subjects and in patients with impaired glucose regulation and with newly diagnosed and untreated type 2 diabetes","volume":"88","author":"Pan","year":"2010","journal-title":"Diabetes Res Clin Pract"},{"key":"B58","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.1002916","article-title":"Association of obesity with heart failure outcomes in 11 Asian regions: A cohort study","volume":"16","author":"Chandramouli","year":"2019","journal-title":"PloS Med"},{"key":"B59","doi-asserted-by":"publisher","first-page":"1770","DOI":"10.3390\/ijms18081770","article-title":"Role of omentin, vaspin, cardiotrophin-1, TWEAK and NOV\/CCN3 in obesity and diabetes development","volume":"18","author":"Escot\u00e9","year":"2017","journal-title":"Int J Mol Sci"},{"key":"B60","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2017.06.003","article-title":"New trends on obesity and NAFLD in Asia","volume":"67","author":"Fan","year":"2017","journal-title":"J Hepatol"}],"container-title":["Frontiers in Endocrinology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2023.1073498\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,4,17]],"date-time":"2023-04-17T06:01:09Z","timestamp":1681711269000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2023.1073498\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,4,17]]},"references-count":60,"alternative-id":["10.3389\/fendo.2023.1073498"],"URL":"https:\/\/doi.org\/10.3389\/fendo.2023.1073498","relation":{},"ISSN":["1664-2392"],"issn-type":[{"value":"1664-2392","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,4,17]]},"article-number":"1073498"}}